KHCM
ADAP

Kettle Hill Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Kettle Hill Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-261,411
Closed -$382K – 55
2022
Q4 		$382K Buy
261,411
+8,277
+3% +$13.4K 0.08% 44
2022
Q3 		$272K Buy
+253,134
New +$465K 0.06% 63

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Kettle Hill Capital Management's ADAP Position: Q1 2023 in Review

Kettle Hill Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2023, closing a stake of 261,411 shares — an estimated $382K sold.

Kettle Hill Capital Management first reported a position in ADAP in Q3 2022 and held it in 2 quarters. The position peaked at $382K in Q4 2022. 65 funds tracked by Wall St. Rank hold ADAP as of Q1 2023.

  • Kettle Hill Capital Management reported no remaining Adaptimmune Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Kettle Hill Capital Management sold 261,411 Adaptimmune Therapeutics shares in Q1 2023, an estimated $382K.
  • Kettle Hill Capital Management first reported a position in Adaptimmune Therapeutics in Q3 2022 and held it in 2 quarters.
  • Kettle Hill Capital Management's Adaptimmune Therapeutics position peaked at $382K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2023.

Based on Kettle Hill Capital Management's 13F filing for Q1 2023, filed 15 May 2023.